Dec'04 | Dec'05 | Dec'06 | Dec'07 | Dec'08 | Dec'09 | Dec'10 | Dec'11 | Dec'12 | Dec'13 | Dec'14 | Dec'15 | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Free Cash Flow margin | 21.1% | 32.4% | 22.6% | 4.9% | (61.7%) | 0.6% | 31.9% | 28.8% | 23.1% | 35.2% | 23.9% | 22.7% | 37.6% | 22.5% | 36.5% | (20.0%) | 46.9% | 28.3% | 34.3% | 32.1% |
Discover the top 20 best undervalued stocks to buy for Jan 2025, listed on the Nasdaq or NYSE.
Discover the top 20 best undervalued large-cap growth stocks to buy for Jan 2025, listed on the Nasdaq or NYSE.
Discover the top 20 best undervalued high-yield dividend stock that offers both growth potential and attractive dividend returns for Jan 2025.
As of today, Microsoft Corp's last 12-month Free Cash Flow margin is 32.6%, based on the financial report for Sep 30, 2024 (Q3 2024). The average annual Free Cash Flow margin for United Therapeutics Corporation have been 33.9% over the past three years, and 32.0% over the past five years.
As of today, United Therapeutics Corporation's Free Cash Flow margin is 32.6%, which is higher than industry median of (753.4%). It indicates that United Therapeutics Corporation's Free Cash Flow margin is Good.